FDA begins approval procedure of the first antibody biosimilar, Celltrion’s ‘Remsima’
Through its website, the U.S. Food and Drug Administration(hereinafter referring to FDA) announced that it is expected to hold the Arthritis Advisory Committee at the FDA White Oak Campus in Maryland and discuss matters about ‘Remsima,’ an autoimmune disease treatment, on the 9th of February.
As...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
